Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer

  1. Carter J Barger
  2. Linda Chee
  3. Mustafa Albahrani
  4. Catalina Munoz-Trujillo
  5. Lidia Boghean
  6. Connor Branick
  7. Kunle Odunsi
  8. Ronny Drapkin
  9. Lee Zou
  10. Adam R Karpf  Is a corresponding author
  1. University of Nebraska Medical Cancer, United States
  2. University of Nebraska Medical Center, United States
  3. Roswell Park Comprehensive Cancer Center, United States
  4. University of Pennsylvania Perelman School of Medicine, United States
  5. Massachusetts General Hospital Cancer Center, Harvard Medical School, United States
  6. University of Nebraska Medical Center;, United States

Abstract

The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form of human ovarian cancer, and is linked to copy number gains at chromosome 12p13.33. We show that FOXM1 is co-amplified and co-expressed with RHNO1, a gene involved in the ATR-Chk1 signaling pathway that functions in the DNA replication stress (RS) response. We demonstrate that FOXM1 and RHNO1 are head-to-head (i.e. bidirectional) genes (BDG) regulated by a bidirectional promoter (BDP) (named F/R-BDP). FOXM1 and RHNO1 each promote oncogenic phenotypes in HGSC cells, including clonogenic growth, DNA homologous recombination repair (HR), and poly-ADP ribosylase (PARP) inhibitor resistance. FOXM1 and RHNO1 are one of the first examples of oncogenic BDG, and therapeutic targeting of FOXM1/RHNO1 BDG is a potential therapeutic approach for ovarian and other cancers.

Data availability

All data generated are found within the manuscript and supporting files. sc-RNA-seq data is deposited in GEO.

The following previously published data sets were used
    1. Ann-Marie Patch 1
    2. Elizabeth L Christie 2
    3. Dariush Etemadmoghadam 3
    4. Dale W Garsed 2
    5. Joshy George 4
    6. Sian Fereday 2
    7. Katia Nones 1
    8. Prue Cowin 2
    9. Kathryn Alsop 2
    10. Peter J Bailey 5
    11. Karin S Kassahn 6
    12. Felicity Newell 7
    13. Michael C J Quinn 1
    14. Stephen Kazakoff 1
    15. Kelly Quek 7
    16. Charlotte Wilhelm-Benartzi 8
    17. Ed Curry 8
    18. Huei San Leong 2
    19. Australian Ovarian Cancer Study Group; Anne Hamilton 9
    20. Linda Mileshkin 10
    21. George Au-Yeung 2
    22. Catherine Kennedy 11
    23. Jillian Hung 11
    24. Yoke-Eng Chiew 11
    25. Paul Harnett 12
    26. Michael Friedlander 13
    27. Michael Quinn 14
    28. Jan Pyman 14
    29. Stephen Cordner 15
    30. Patricia O'Brien 15
    31. Jodie Leditschke 15
    32. Greg Young 15
    33. Kate Strachan 15
    34. Paul Waring 16
    35. Walid Azar 2
    36. Chris Mitchell 2
    37. Nadia Traficante 2
    38. Joy Hendley 2
    39. Heather Thorne 2
    40. Mark Shackleton 10
    41. David K Miller 7
    42. Gisela Mir Arnau 2
    43. Richard W Tothill 10
    44. Timothy P Holloway 2
    45. Timothy Semple 2
    46. Ivon Harliwong 7
    47. Craig Nourse 7
    48. Ehsan Nourbakhsh 7
    49. Suzanne Manning 7
    50. Senel Idrisoglu 7
    51. Timothy J C Bruxner 7
    52. Angelika N Christ 7
    53. Barsha Poudel 7
    54. Oliver Holmes 1
    55. Matthew Anderson 7
    56. Conrad Leonard 1
    57. Andrew Lonie 17
    58. Nathan Hall 18
    59. Scott Wood 1
    60. Darrin F Taylor 7
    61. Qinying Xu 1
    62. J Lynn Fink 7
    63. Nick Waddell 7
    64. Ronny Drapkin 19
    65. Euan Stronach 8
    66. Hani Gabra 8
    67. Robert Brown 8
    68. Andrea Jewell 20
    69. Shivashankar H Nagaraj 7
    70. Emma Markham 7
    71. Peter J Wilson 7
    72. Jason Ellul 2
    73. Orla McNally 11
    74. Maria A Doyle 2
    75. Ravikiran Vedururu 2
    76. Collin Stewart 21
    77. Ernst Lengyel 20
    78. John V Pearson 1
    79. Nicola Waddell 1
    80. Anna deFazio 11
    81. Sean M Grimmond 5
    82. David D L Bowtell
    (2015) HGSC RNA-seq
    EGAD00001000877.

Article and author information

Author details

  1. Carter J Barger

    Eppley Institute, University of Nebraska Medical Cancer, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Linda Chee

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Mustafa Albahrani

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Catalina Munoz-Trujillo

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Lidia Boghean

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Connor Branick

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Kunle Odunsi

    Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Ronny Drapkin

    University of Pennsylvania Perelman School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Lee Zou

    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Adam R Karpf

    Eppley Institute, University of Nebraska Medical Center;, Omaha, United States
    For correspondence
    adam.karpf@unmc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0866-0666

Funding

National Institutes of Health (P30CA036727)

  • Adam R Karpf

Rivkin Center for Ovarian Cancer

  • Adam R Karpf

Fred & Pamela Pamela Buffett Cancer Center

  • Adam R Karpf

UNMC Fellowship

  • Carter J Barger

McKinsey Ovarian Cancer Research Fund

  • Adam R Karpf

UNMC Core Facility Users Grant

  • Adam R Karpf

National Institutes of Health (T32CA009476)

  • Carter J Barger

National Institutes of Health (F99CA212470)

  • Carter J Barger

National Institutes of Health (P50CA228991)

  • Ronny Drapkin

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Barger et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,546
    views
  • 343
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Carter J Barger
  2. Linda Chee
  3. Mustafa Albahrani
  4. Catalina Munoz-Trujillo
  5. Lidia Boghean
  6. Connor Branick
  7. Kunle Odunsi
  8. Ronny Drapkin
  9. Lee Zou
  10. Adam R Karpf
(2021)
Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer
eLife 10:e55070.
https://doi.org/10.7554/eLife.55070

Share this article

https://doi.org/10.7554/eLife.55070

Further reading

    1. Cancer Biology
    Yang Peng, Jing Yang ... Liang Weng
    Research Article

    Background:

    Cervical adenocarcinoma (ADC) is more aggressive compared to other types of cervical cancer (CC), such as squamous cell carcinoma (SCC). The tumor immune microenvironment (TIME) and tumor heterogeneity are recognized as pivotal factors in cancer progression and therapy. However, the disparities in TIME and heterogeneity between ADC and SCC are poorly understood.

    Methods:

    We performed single-cell RNA sequencing on 11 samples of ADC tumor tissues, with other 4 SCC samples served as controls. The immunochemistry and multiplexed immunofluorescence were conducted to validate our findings.

    Results:

    Compared to SCC, ADC exhibited unique enrichments in several sub-clusters of epithelial cells with elevated stemness and hyper-malignant features, including the Epi_10_CYSTM1 cluster. ADC displayed a highly immunosuppressive environment characterized by the enrichment of regulatory T cells (Tregs) and tumor-promoting neutrophils. The Epi_10_CYSTM1 cluster recruits Tregs via ALCAM-CD6 signaling, while Tregs reciprocally induce stemness in the Epi_10_CYSTM1 cluster through TGFβ signaling. Importantly, our study revealed that the Epi_10_CYSTM1 cluster could serve as a valuable predictor of lymph node metastasis for CC patients.

    Conclusions:

    This study highlights the significance of ADC-specific cell clusters in establishing a highly immunosuppressive microenvironment, ultimately contributing to the heightened aggressiveness and poorer prognosis of ADC compared to SCC.

    Funding:

    Funded by the National Natural Science Foundation of China (82002753; 82072882; 81500475) and the Natural Science Foundation of Hunan Province (2021JJ40324; 2022JJ70103).

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.